Amyotrophic Lateral Sclerosis (ALS)

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
Who is this for?
Show terms as
4FDA treatments3Active trials32Specialists8Treatment centers2Financial resources

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Amyotrophic Lateral Sclerosis (ALS) is treated with 3 medications in our database, including RADICAVA, RADICAVA ORS, Finzala, ZELVYSIA. 3 of these have manufacturer assistance programs available to help reduce out-of-pocket costs. Medications are manufactured by Mitsubishi Tanabe, Mayne, Chiesi. Patients and caregivers can find copay cards, patient assistance programs, and travel grants for Amyotrophic Lateral Sclerosis (ALS) treatment below.

Also known as:

Inheritance

Variable

Can be inherited in different ways depending on the underlying gene

Age of Onset

Adult

Begins in adulthood (age 18 or older)

NORD ↗

FDA & Trial Timeline

7 events
Jan 2026Intestinal Microbiome Transplant in ALS

Duke University — PHASE1, PHASE2

TrialRECRUITING
Dec 2024Transcranial Static Magnetic Stimulation (tSMS) and Potential Theranostic Biomarkers in Amyotrophic Lateral Sclerosis.

Campus Bio-Medico University — NA

TrialRECRUITING
Dec 2023A Phase 1, SAD and MAD Study to Evaluate the Safety and Tolerability of FB418

1ST Biotherapeutics, Inc. — PHASE1

TrialRECRUITING
Sep 2022

Relyvrio: FDA approved

Treatment of amyotrophic lateral sclerosis (ALS) in adults

FDAcompleted
Dec 2019

Tiglutik: FDA approved

TIGLUTIK is indicated for the treatment of amyotrophic lateral sclerosis (ALS).

FDAcompleted
Nov 2019

EXSERVAN: FDA approved

EXSERVAN is indicated for the treatment of amyotrophic lateral sclerosis (ALS).

FDAcompleted
May 2017

Radicava: FDA approved

Treatment of amyotrophic lateral sclerosis (ALS)

FDAcompleted

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

4 available

Qalsody

tofersen· Biogen Inc.Accelerated Approval

QALSODY is indicated for the treatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene.

Tiglutik

riluzole oral suspension· Italfarmaco SpAOrphan Drug

TIGLUTIK is indicated for the treatment of amyotrophic lateral sclerosis (ALS).

EXSERVAN

riluzole oral film· Aquestive TherapeuticsOrphan Drug

EXSERVAN is indicated for the treatment of amyotrophic lateral sclerosis (ALS).

Radicava

edaravone· Tanabe Pharma America Inc.Orphan Drug

Treatment of amyotrophic lateral sclerosis (ALS)

Clinical Trials

3 recruitingView all trials with filters →
Phase 11 trial
A Phase 1, SAD and MAD Study to Evaluate the Safety and Tolerability of FB418
Phase 1
Actively Recruiting
PI: 1STBIO study manager (1ST Biotherapeutics, Inc.) · Sites: Seoul · Age: 1999 yrs
N/A1 trial
Transcranial Static Magnetic Stimulation (tSMS) and Potential Theranostic Biomarkers in Amyotrophic Lateral Sclerosis.
N/A
Actively Recruiting
· Sites: Roma, RM · Age: 1899 yrs

Specialists

Showing 25 of 32View all specialists →
FC
Francesca Luisa Conforti
Specialist
2 Amyotrophic Lateral Sclerosis (ALS) publications
PC
Philippe Corcia
Specialist
3 Amyotrophic Lateral Sclerosis (ALS) publications
MR
Mary-Louise Rogers
Specialist
3 Amyotrophic Lateral Sclerosis (ALS) publications
HK
Hüseyin Can Kaya
Specialist
2 Amyotrophic Lateral Sclerosis (ALS) publications
AA
Abir Alaamel
Specialist
2 Amyotrophic Lateral Sclerosis (ALS) publications
HD
Hatice Değirmenci
Specialist
2 Amyotrophic Lateral Sclerosis (ALS) publications
AM
Amrei Menzel
Specialist
2 Amyotrophic Lateral Sclerosis (ALS) publications
AK
Andrej Kovac
Specialist
2 Amyotrophic Lateral Sclerosis (ALS) publications
LG
Lucas Caldi Gomes
WYOMING, MI
Specialist
2 Amyotrophic Lateral Sclerosis (ALS) publications
LT
Laura Tzeplaeff
Specialist
2 Amyotrophic Lateral Sclerosis (ALS) publications
AK
Anna Konopka
Specialist
2 Amyotrophic Lateral Sclerosis (ALS) publications
LB
Leonard H Van den Berg
Specialist
2 Amyotrophic Lateral Sclerosis (ALS) publications
PD
Philip Van Damme
Specialist
2 Amyotrophic Lateral Sclerosis (ALS) publications
JM
Jakub M Antczak, MD
Krakow, Lesser Poland Voivodeship
Specialist

Rare Disease Specialist

PI on 3 active trials
AG
Ana Galhoz
Specialist
2 Amyotrophic Lateral Sclerosis (ALS) publications
CM
Clara Meijs
Specialist
2 Amyotrophic Lateral Sclerosis (ALS) publications
AB
Andrew Brown
FL
Specialist
2 Amyotrophic Lateral Sclerosis (ALS) publications
TG
Tania F Gendron
FL
Specialist
2 Amyotrophic Lateral Sclerosis (ALS) publications
AC
Adriano Chiò
Specialist
2 Amyotrophic Lateral Sclerosis (ALS) publications
JK
Justin Kwan
PHILADELPHIA, MD
Specialist
2 Amyotrophic Lateral Sclerosis (ALS) publications
PW
Paul Wicks
Specialist
3 Amyotrophic Lateral Sclerosis (ALS) publications
DR
Dylan Ratner
LA
Specialist
3 Amyotrophic Lateral Sclerosis (ALS) publications
KP
Kaitlyn Pierce
NC
Specialist
3 Amyotrophic Lateral Sclerosis (ALS) publications
GP
Gary Pattee
LINCOLN, NE
Specialist
3 Amyotrophic Lateral Sclerosis (ALS) publications

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Financial Resources

2 resources
Qalsody(tofersen)Biogen Inc.

Relyvrio

Amylyx Pharmaceuticals, Inc.

Amyotrophic Lateral Sclerosis (ALS)

Unverified — confirm before calling
copay card
copay assistancePatient Assistance
Accepting applications

Travel Grants

No travel grants are currently matched to Amyotrophic Lateral Sclerosis (ALS).

Search all travel grants →NORD Financial Assistance ↗

Community

Open Amyotrophic Lateral Sclerosis (ALS)Forum →

No community posts yet. Be the first to share your experience with Amyotrophic Lateral Sclerosis (ALS).

Start the conversation →

Latest news about Amyotrophic Lateral Sclerosis (ALS)

No recent news articles for Amyotrophic Lateral Sclerosis (ALS).

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Amyotrophic Lateral Sclerosis (ALS)

What is Amyotrophic Lateral Sclerosis (ALS)?

Amyotrophic Lateral Sclerosis (ALS) is treated with 3 medications in our database, including RADICAVA, RADICAVA ORS, Finzala, ZELVYSIA. 3 of these have manufacturer assistance programs available to help reduce out-of-pocket costs. Medications are manufactured by Mitsubishi Tanabe, Mayne, Chiesi. Patients and caregivers can find copay cards, patient assistance programs, and travel grants for Amyotrophic Lateral Sclerosis (ALS) treatment below.

At what age does Amyotrophic Lateral Sclerosis (ALS) typically begin?

Typical onset of Amyotrophic Lateral Sclerosis (ALS) is adult. Age of onset can vary across affected individuals.

Are there clinical trials for Amyotrophic Lateral Sclerosis (ALS)?

Yes — 3 recruiting clinical trials are currently listed for Amyotrophic Lateral Sclerosis (ALS) on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Amyotrophic Lateral Sclerosis (ALS)?

25 specialists and care centers treating Amyotrophic Lateral Sclerosis (ALS) are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.

What treatment and support options exist for Amyotrophic Lateral Sclerosis (ALS)?

3 patient support programs are currently tracked on UniteRare for Amyotrophic Lateral Sclerosis (ALS). See the treatments and support programs sections for copay assistance, eligibility, and contact details.